Health Catalyst (HCAT) Projected to Release Quarterly Earnings on Thursday

Health Catalyst (NASDAQ:HCAT) is expected to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $55.39 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 5, 2026 at 5:00 PM ET.

Health Catalyst (NASDAQ:HCAT) last released its quarterly earnings results on Thursday, August 6th. The company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.01. The business had revenue of $70.49 million during the quarter, compared to analyst estimates of $69.09 million. Health Catalyst had a negative net margin of 90.61% and a negative return on equity of 1.83%. On average, analysts expect Health Catalyst to post ($0.18) EPS for the current fiscal year and ($0.19) EPS for the next fiscal year.

Health Catalyst Stock Down 8.9%

NASDAQ:HCAT opened at $1.44 on Wednesday. The company has a debt-to-equity ratio of 1.51, a current ratio of 2.70 and a quick ratio of 2.70. The firm has a 50-day moving average of $1.72 and a two-hundred day moving average of $1.71. Health Catalyst has a 1-year low of $0.96 and a 1-year high of $3.36.

Insider Buying and Selling

In other Health Catalyst news, CEO Simeon Kohl bought 59,000 shares of the stock in a transaction on Monday, September 14th. The stock was purchased at an average price of $1.79 per share, for a total transaction of $105,610.00. Following the completion of the purchase, the chief executive officer directly owned 2,856,385 shares in the company, valued at approximately $5,112,929.15. This trade represents a 2.11% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 19.40% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on HCAT. Citigroup cut their price target on Health Catalyst from $2.50 to $2.00 and set a “neutral” rating on the stock in a research note on Tuesday, August 11th. Wells Fargo & Company dropped their price objective on Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th. Canaccord Genuity Group lowered Health Catalyst from a “buy” rating to a “hold” rating and cut their target price for the company from $3.00 to $1.80 in a research report on Thursday, August 20th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Health Catalyst in a research note on Monday, October 26th. Two analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Health Catalyst presently has a consensus rating of “Hold” and an average price target of $2.01.

About Health Catalyst

Health Catalyst, Inc is a healthcare technology company that provides data and analytics solutions to help healthcare organizations improve clinical outcomes, operational efficiency and financial performance. Its customers include hospitals, health systems, medical groups and other healthcare organizations seeking to integrate and analyze data from across their operations.

The company’s offerings are built around its Health Catalyst Data Operating System, a cloud-based platform designed to combine information from electronic health records, financial systems and other sources.